TG's Briumvi is an anti-CD20 monoclonal antibody that was approved by the FDA for patients with RMS in December 2022 (and by the EC in June 2023) after it demonstrated superiority to Sanofi's oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback